Trial reportWorld journal of urology2026
Efficacy and safety of 6.3-Fr versus 8.6-Fr disposable digital flexible ureteroscopes for pediatric upper urinary tract stones ≤ 2 cm: a randomized controlled trial.
Trial report in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06628765 (Two Types of Single-use Flexible Ureteroscopies for the Treatment of Upper Urinary Tract Stones in Children), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Two Types of Single-use Flexible Ureteroscopies for the Treatment of Upper Urinary Tract Stones in Children: A Single-center Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo compare the efficacy and safety of 6.3-Fr versus 8.6-Fr disposable digital flexible ureteroscopes for pediatric upper urinary tract stones ≤ 2 cm.
methodsA single-surgeon, prospective, randomized controlled trial was conducted at our center between September 2024 and September 2025. Children undergoing surgery for upper urinary tract stones were randomized (1:1) to the 6.3-Fr or 8.6-Fr group. Inclusion criteria included: (1) age < 18 years; (2) upper urinary tract stones ≤ 2 cm confirmed by Computed Tomography (CT); and (3) informed consent obtained. Exclusion criteria were: (1) congenital anomalies of the kidney and urinary tract (CAKUT); (2) severe renal insufficiency; (3) major cardiopulmonary dysfunction or coagulopathy; and (4) ipsilateral ureteroscopic procedures or double-J (DJ) stent placement within the previous 3 months. Preoperative characteristics, operative time, stone-free rate (SFR) at 4 weeks, perioperative complications, number of anesthesia events, and hospitalization-related parameters were collected. The study was registered at ClinicalTrials.gov (NCT06628765).
resultsForty children were included, with 20 patients in each group. Baseline demographics and stone characteristics were comparable. The first-attempt ureteroscope insertion success rate was higher in the 6.3-Fr group than in the 8.6-Fr group (60.0% vs. 20.0%, p = 0.010). During second-stage procedures, sheathless retrograde intrarenal surgery (RIRS) was more frequently performed in the 6.3-Fr group (62.5% vs. 12.5%, p = 0.021). Median hospitalization costs were significantly lower in the 6.3-Fr group (13,510 vs. 17,643 CNY, p = 0.001). The number of anesthesia events and the rate of postoperative stent placement also differed significantly between groups (p < 0.05). Both operative time, length of hospital stay, SFR at 4 weeks, and postoperative complications did not differ significantly (p > 0.05).
conclusionThis study provides the first evidence supporting the efficacy and safety of the 6.3-Fr disposable flexible ureteroscope in children. The smaller-diameter device was associated with higher first-pass insertion success, fewer anesthesia events, and reduced hospitalization costs, offering clear advantages in pediatric RIRS.
Indexed as
Identifiers
41876909What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.